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Abstract 
Background: Modified Erxian decoction (MEXD), i.e., Erxian  decoction (EXD) with Fructus Schisandrae chinensis (Wu 
Wei Zi) added, has been used to alleviate menopausal symptoms. This study aimed to investigate the effects of MEXD 
on menopausal sweating and serum hormone levels in a rat model of menopause after oral administration of MEXD.
Methods: Quality control of MEXD was conducted by employing a reversed-phase high performance liquid chro-
matography column. The three treatment groups received oral administration of MEXD in 0.5% sodium carboxyl-
methyl cellulose (CMC-Na) at three different doses (5.5, 11, and 22 g/kg body weight) once-daily for 6 consecutive 
weeks, with 10 animals per group. Huangqijing oral liquor (5 mL/kg) prepared from the roots of Huang qi (Astragalus 
membranaceus) with an antiperspirant effect was used as a positive control. The negative control group received 
the same volume of vehicle (0.5% CMC-Na). Ten 3-month-old Sprague–Dawley rats were used as a young group for 
comparison with the treatment groups (12–14 months old rats). Blood was collected from all animals after 3–6 weeks 
of treatment. At the end of the treatment, the uterine weight, ovarian weight, and body weight were recorded. Serum 
malondialdehyde contents and superoxide dismutase activities were determined by thiobarbituric acid colorimet-
ric assays and chemoluminescence assays, respectively. Serum levels of estradiol, follicle-stimulating hormone, and 
luteinizing hormone were measured by radioimmunoassays. Rat foot pad assays were used to determine the antiper-
spirant activity of MEXD and histological examinations were conducted on plantar sweat glands.
Results: Treatment with MEXD (11 g/kg) significantly inhibited sweat excretion in the menopause model rats after 
treatment for 3 (P = 0.0026) and 6 (P < 0.0001) weeks. The decoction markedly decreased the number of secretory 
cells in plantar sweat glands. In addition, MEXD (11 g/kg) significantly increased the serum estradiol levels (P < 0.001) 
and superoxide dismutase activities (P = 0.0405). Furthermore, MEXD (11 g/kg) markedly decreased the serum levels 
of follicle-stimulating hormone (P = 0.001), luteinizing hormone (P = 0.0213), and malondialdehyde (P = 0.01).
Conclusion: Modified Erxian decoction significantly inhibited sweat excretion, regulated serum levels of pituitary 
gonadotropins and estradiol, and exhibited antioxidative effects in a rat model of menopause.
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Background
Menopausal syndrome refers to symptoms that appear 
during the menopausal transition, including hot flashes, 
sweating, dysphoria, and insomnia. Sweating is the main 
menopausal vasomotor symptom, and can significantly 
affect the quality of life in middle-aged females [1]. More 
than 80% of middle-aged women suffer from vasomo-
tor symptoms, including hot flashes and night sweats, 
during menopause [2, 3]. One of the underlying mecha-
nisms involves decreased secretion of sex hormones [4] 
through deterioration of ovarian functions in an age-
related free radical-predominant environment [5], which 
in turn elevates the production of the gonadotropins 
luteinizing hormone (LH) and follicle-stimulating hor-
mone (FSH) [6]. This hormonal dysregulation eventually 
results in autonomic dysfunction, thereby disturbing the 
coordination of the neuroendocrine system. Hormone 
replacement therapy (HRT) has been adopted as the con-
ventional treatment for menopausal syndrome to com-
pensate for the reduction in ovarian estrogen production. 
However, concerns about increased risks of some chronic 
diseases, such as breast cancer, heart attack, and stroke, 
with HRT have stimulated interest in the development of 
safer alternative therapies [7].
Herbal medicines with estrogenic activity or enriched 
with phytoestrogens have frequently been employed as 
complementary therapies to relieve menopausal symp-
toms [8–15]. However, only a few studies have investi-
gated the treatment of menopausal vasomotor symptoms 
using herbal medicines.
In Chinese medicine, menopausal syndrome is attrib-
uted to insufficiency of kidney essence, and deficiency 
of kidney yin and yang. At the age of about 49  years, 
the kidney qi gradually becomes insufficient, the func-
tion of ChongRen declines, and Tian gui (an important 
reproduction essence) begins to dry up, thereby causing 
the loss of reproductive capacity. Clinically, menopau-
sal women often suffer from menstrual disorders, hot 
flashes, and night sweats. Erxian decoction (EXD) has 
been used in the treatment of menopausal syndrome, and 
consists of six Chinese medicinal herbs, namely rhizoma 
Curculigo orchioides (Xian mao), herba Epimedium brev-
icornum (Yin yang huo), radix Morinda officinalis (Ba ji 
tian), radix Angelica sinensis (Dang gui), cortex Phello-
dendron chinense (Huang bo), and rhizome Anemarrhena 
asphodeloides (Zhi mu) [11, 16]. In EXD, constituent 
herbs C. orchioides, E. brevicornum, and M. officinalis 
can warm the kidney yang, and was used to restore the 
kidney yin. A. asphodeloides goes into the central part of 
the body, where it removes the heat of the stomach and 
nourishes the stomach Yin. P. chinense goes into the lower 
part of the body, nourishes the kidney yin, and brings 
pathogenic fire back to the kidneys. A. sinensis, a medi-
cine that nourishes blood, can also restore qi, and was 
used to restore both blood and qi. The night sweats dur-
ing menopause arise through the deficiency of kidney yin 
and yang. However, a clinical study reported that EXD 
alone did not exert marked effects on perspiration [17]. 
The fruit of Schisandrae chinensis (Wu wei zi), with the 
pharmacologic effect of arresting discharge to decrease 
sweating, is commonly used to treat insomnia and as an 
antiperspirant clinically [17, 18]. A clinical study showed 
that modified EXD (MEXD) consisting of EXD with 
other added herbs, including the fruit of S. chinensis, can 
relieve menopausal sweating [18, 19]. However, related 
basic research data have not yet been reported.
This study aimed to investigate the effects of MEXD 
on menopausal sweating and serum hormone pro-
files in menopausal rats after oral administration of 
MEXD. We hypothesized that MEXD would allevi-
ate the sweating symptom in menopausal females via 
increased expression of antioxidative enzymes and 
estradiol (E2), and decreased production of serum gon-
adotropins, LH, FSH, and malondialdehyde (MDA). 
As the study model, we used 12–14-month-old aged 
menopausal Sprague-Dawley (SD) rats with irregular 
estrous cycles, as well as elevated serum FSH levels and 
decreased serum E2 levels, in accordance with our pre-
vious publication [11]. The effects of MEXD on sweat 
excretion, uterine and ovarian weights, serum levels of 
E2, FSH, LH, and MDA, and activity of serum super-
oxide dismutase (SOD) were determined. The effects 
of MEXD on the morphology of plantar sweat glands 
were also examined. Functional assays of sweating after 
MEXD treatment were performed to validate its thera-
peutic efficacy.
Methods
Herbal materials and MEXD extract
The seven medicinal plants of MEXD, namely C. 
orchioides, E. brevicornum, M. officinalis, A. sinensis, P. 
chinense, A. asphodeloides and S. Chinensis (voucher 
no. CME140706-03, CME150906-11, CME050406-02, 
CME090706-12, CME100606-09, CME180806-01 and 
JWE030806-05 respectively) were collected from vari-
ous sources and their identities were confirmed by Dr. 
Yanbo Zhang, School of Chinese Medicine, the Univer-
sity of Hong Kong based on their morphological appear-
ances. One kilogram of each of the six component herbs 
of EXD, and 1  kg of S. Chinensis fruit (composition 
ratio = 12:12:10:10:9:9:12) was decocted separately with 
distilled water in a ratio of 10:1 (v/w) at 100  °C for one 
hour, and the extraction was repeated twice. The proce-
dures followed those of our previous publication [20, 21].
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Quality control and high performance liquid 
chromatography (HPLC)
For evaluation of the quality consistency of MEXD 
extracts, nine chemical standards were utilized as mark-
ers, namely berberine, ferulic acid, icariin, jatrorrhizine, 
palmatine, schizandrol, schizandrol B, schizandrin A 
and schizandrin B. All these standard chemicals were 
purchased from Beijing Century Biotechnology Co., Ltd 
(Beijing, China). These nine selected chemical standards 
and three batches of MEXD extracts were accurately 
weighed out and extracted with 10  mL of methanol in 
a water bath at 60  °C for 15 min, followed by ultrasoni-
cation for 30  min. After centrifugation at 1500×g for 
15  min, the supernatant was filtered with a 0.45  µm 
Millex® Syringe filter unit, and then injected in a volume 
of 10 μL into a HPLC. Reproducibility and linearity were 
estimated by repetitive injections. The external standard 
method, employing a series of mixed standard solutions 
ranging in concentration from 4.0625 to 145 μg/mL, was 
utilized. The column used was a reversed-phase column 
(XBridge® C18, 5 µm, 250 mm × 4.6 mm i.e., Waters, Ire-
land). The mobile phase consisted of acetonitrile (A) and 
0.05% sodium dodecyl sulfate (SDS) in 0.1% acetic acid 
(B) using a gradient program of 95–70% (B) in 0–30 min, 
70–70% (B) in 30–35  min, 70–50% (B) in 35–45  min, 
50–45% (B) in 50–70 min, 45–35% (B) in 70–90 min, and 
35–30% (B) in 90–100  min. The flow rate was 1.0  mL/
min. The UV spectra from 200 to 400 nm were acquired 
with the photodiode array detector and chromatogram at 
254 nm was extracted. Peak integration was analyzed by 
the software of Empower Pro, Waters®.
Experimental animals and drug treatment
Sixty-five female SD rats aged 12–14  months (weight: 
290–370 g) and 10 SD rats aged 3 months (weight: 160–
190 g) were obtained from the Animal Center of Nanjing 
Qinglongshan. The animals were housed in an air-con-
ditioned room at an ambient temperature of 24  °C and a 
relative humidity of 50–65% under automatic 12- /12-h 
light/dark cycles. All efforts were made to minimize suf-
fering of the animals and to reduce the number of ani-
mals used. Animal experiment has been conducted in 
China Pharmaceutical University since 2007, which was in 
accordance with the regulations for animal care and use in 
Department of Health, the Government of the Hong Kong 
Special Administrative Region (Reference no. 07-298 and 
09-92) (Additional files 1, 2). The animal studies were per-
formed following the ARRIVE guideline (Additional file 3).
Using vaginal smear tests, 50 of the 65 rats with both 
irregular estrous cycles and lowered serum E2 levels were 
classified as menopausal rats, and selected as the experi-
mental animals. These rats were arbitrarily divided into a 
negative control group and four treatment groups, with 
10 rats per group. The four treatment groups received oral 
administration of MEXD in 0.5% sodium carboxylmethyl 
cellulose (CMC-Na) at three different doses (5.5, 11, and 
22  g/kg body weight) or Huangqijing oral liquor at 5  mL/
kg (Z32020370; Yangtze River Pharmaceutical Co. Ltd.), 
prepared from the roots of Astragalus membranaceus 
with an antiperspirant effect, as a positive control once-
daily for 6 consecutive weeks. The drug ratios in MEXD 
(12:12:10:10:9:9:12), namely rhizoma Curculigo orchioides 
(Xian mao) 12 g, herba Epimedium brevicornum (Yin yang 
huo) 12 g, radix Morinda officinalis (Ba ji tian) 10 g, radix 
Angelica sinensis (Dang gui) 10  g, cortex Phellodendron 
chinense (Huang bo) 9  g, rhizome Anemarrhena asphode-
loides (Zhi mu) 9 g, and Fructus Schisandrae chinensis (Wu 
Wei Zi) 12 g are commonly used clinically [20]. The dosage 
of 11 g/kg/day applied to rats corresponded to an equivalent 
dosage in humans [22], and thus three dosages of MEXD 
(5.5, 11, and 22 g/kg) were selected for this study. The nega-
tive control group received the same volume of vehicle (0.5% 
CMC-Na). The 10 SD rats aged 3  months were used as a 
young group for comparison with the aged rats.
Rat foot pad assay for antiperspirant activity
Sweat secretion in the rats was detected by rat foot pad 
assays after MEXD treatment for 3–6 weeks. The method 
was originally developed by Helman et  al. [23] and has 
been used in previous studies [23–25]. Briefly, the foot 
pads of all rats were cleaned with 70% ethanol to remove 
debris, and then swabbed with iodine solution (2% w/v in 
95% ethanol). After evaporation of the ethanol at room 
temperature, the foot pads were coated with castor oil 
containing 50% starch for 15 min. As the sweating parts 
of the foot pads showed coloration by starch–iodine reac-
tions, the colored points on the foot pads (i.e., number of 
sweat glands) were enumerated under a microscope and 
the degree of perspiration was measured.
Measurement of serum antioxidant biochemical 
parameters and hormones
At 24  h after the last gavage, blood samples were col-
lected from the femoral artery of the rats to determine 
the serum levels of MDA, SOD activity, E2, FSH, and 
LH. The collected blood was centrifuged at 1000×g for 
10 min and the serum supernatant was stored at −20 °C 
until analysis. The serum MDA concentrations and SOD 
activities were determined by thiobarbituric acid colori-
metric assays and chemoluminescence assays (Nanjing 
Jiancheng Bioengineering Institute, Nanjing, China), 
respectively. The serum levels of E2, FSH, and LH were 
measured by radioimmunoassays using an E2 assay kit 
(Cat. No. B05PZA), FSH assay kit (Cat. No. B03PZB), and 
LH assay kit (Cat. No. B04PZB) from Beijing North Insti-
tute of Biological Technology (China), respectively.
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Measurement of organ indices
All rats were killed by cervical dislocation after blood collec-
tion. The uteri and ovaries were excised and weighed imme-
diately on an electronic balance. The organ indices were 
calculated by dividing the organ weights by the body weight.
Histological examination
The epidermis of the foot pads was dissected into pieces, 
fixed in 10% formalin, and processed for paraffin section-
ing. Tissue sections were stained with hematoxylin and 
eosin and examined under an optical microscope [26].
Statistical analysis
All data were expressed as the mean ±  standard devia-
tion. Differences among groups were evaluated for sta-
tistical significance by one-way ANOVA followed by a 
Tukey multiple-comparisons test using GraphPad Prism 




The UV spectra of all eluted peaks from 200 to 400 nm in 
chromatograms of MEXD were measured by photodiode 
array detection, and the majority of the detectable peaks 
in the HPLC chromatograms were found at 254 nm. The 
chromatograms were thus extracted at the detection wave-
length of 254 nm. A chromatographic fingerprint indicat-
ing the elution peaks of nine standard compounds and 
other common peaks is shown in Fig.  1. Three batches 
of MEXD preparations were examined by HPLC using 
the optimum running conditions. The inter assay relative 
standard deviation (RSD) values were less than 5% for all of 
the standard compounds. The results are shown in Table 1.
Antioxidant activity of MEXD in menopausal rats
The serum SOD activities were significantly lower (Fig. 2) 
and the serum MDA levels were significantly higher 
(Fig.  3) in the control group compared with the young 
Fig. 1 Overlaid HPLC chromatographic fingerprint of three batches of MEXD extract monitored at 254 nm. Nine standard compounds and their 
respective retention times are shown
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rats. Treatment with MEXD at all dosages and Huangqi-
jing was able to significantly reverse these changes.
Regulatory effects of MEXD on serum gonadotropic 
and gonadal hormones in menopausal rats
Significantly reduced serum E2 levels (Fig.  4) accompa-
nied by increased serum levels of FSH (Fig.  5) and LH 
(Fig. 6) were found in the menopausal rats in the control 
group compared with the young rats. After treatment 
with MEXD at 11 g/kg, the serum E2 levels increased sig-
nificantly. Meanwhile, treatment with MEXD at 5.5 and 
11  g/kg decreased the serum LH and FSH levels com-
pared with the control group.  
Effects of MEXD on organ indices of the ovaries and uteri
Compared with the young rats, the organ indices of the 
ovaries of the menopausal rats in the control group were 
significantly decreased. However, the organ indices of the 
ovaries and uteri in all four treatment groups (MEXD 
and Huangqijing) did not differ significantly compared 
with those in the control group (Table 2). These findings 
Table 1 Contents of nine compound standards in MEXD
Standards (μg/mg) Batch 1 Batch 2 Batch 3 Mean Standard deviation Relative standard deviation (%)
Berberine 0.961 0.945 0.924 0.943 0.019 1.983
Ferulic acid 0.200 0.189 0.191 0.193 0.006 3.137
Icariine 0.414 0.411 0.408 0.411 0.003 0.783
Jatrorrhizine 0.054 0.054 0.053 0.054 0.000 0.078
Palmatine 0.611 0.598 0.586 0.598 0.013 2.106
Schizandrol A 0.341 0.334 0.354 0.343 0.010 2.990
Schizandrol B 0.114 0.109 0.118 0.113 0.004 3.891
Schizandrin A 0.107 0.107 0.107 0.107 0.000 0.217
Schizandrin B 0.136 0.134 0.133 0.134 0.002 1.469
Fig. 2 Serum levels of SOD in menopausal rats after MEXD treatment 
(n = 10, mean ± standard deviation). One-way ANOVA followed by 
multiple comparisons. *P < 0.05, **P ≤ 0.01 compared with control. 
Young rats vs. control: P = 0.0026, MEXD (22 g/kg) vs. control: 
P = 0.0474
Fig. 3 Serum levels of MDA in menopausal rats after MEXD treat-
ment (n = 10, mean ± standard deviation). One-way ANOVA fol-
lowed by multiple comparisons *P < 0.05, **P ≤ 0.01 compared with 
control. Young rats vs. control: P = 0.0013, MEXD (11 g/kg) vs. control: 
P = 0.01
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indicated that MEXD treatment exerted no observable 
adverse effects on the ovaries and uteri.
Antiperspirant activity of MEXD on the foot pads 
of menopausal rats
Sweat secretion of rat foot pads was determined by the 
iodine–starch reaction in all groups and the results are 
shown in Fig. 7. The number of active sweat glands in the 
menopausal rats in the control group was significantly 
higher than that in the young rats (P  =  0.0012). At the 
Fig. 4 Serum levels of E2 in menopausal rats after MEXD treatment 
(n = 10, mean ± standard deviation). One-way ANOVA followed by 
multiple ***P < 0.001 compared with control. Young rats vs. control: 
P < 0.0001, MEXD (11 g/kg) vs. control: P < 0.0001
Fig. 5 Serum levels of FSH in menopausal rats after MEXD treatment 
(n = 10, mean ± standard deviation).One-way ANOVA followed 
by multiple comparisons. **P ≤ 0.01, ***P < 0.001 compared with 
control. Young rats vs. control: P = 0.001, MEXD (5.5 g/kg) vs. control: 
P = 0.005, MEXD (11 g/kg) vs. control: P = 0.0008
Fig. 6 Serum levels of LH in menopausal rats after MEXD treatment 
(n = 10, mean ± standard deviation). One-way ANOVA followed by 
multiple **P ≤ 0.01 and *P < 0.05 compared with control. Young rats 
vs. control: P = 0.0017, MEXD (5.5 g/kg) vs. control: P = 0.004, MEXD 
(11 g/kg) vs. control: P = 0.0213, Huangqijing vs. control: P = 0.0131
Table 2 Organ indices of  ovaries and  uteruses in  meno-
pausal rats after MEXD treatment (n = 10, mean ± stand-
ard deviation)
** P < 0.001 (one way ANOVA, n = 10) compared with control
Group Organ index
Uterus (×10−3) Ovary (×10−4)
Young 2.33 ± 0.81 3.38 ± 0.33**
Control 2.34 ± 0.58 2.30 ± 0.51
MEXD (5.5 g/kg) 1.80 ± 0.35 2.37 ± 0.67
MEXD (11 g/kg) 1.88 ± 0.32 2.21 ± 0.25
MEXD (22 g/kg) 2.23 ± 0.63 2.54 ± 0.84
Huangqijing (5 mL/kg) 2.00 ± 0.38 2.27 ± 0.47
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dosage of 11 g/kg, MEXD significantly decreased the num-
ber of sweat glands in the menopausal rats after 3 weeks of 
treatment. All dosages of MEXD were able to inhibit sweat 
secretion, especially the dose of 11  g/kg, which signifi-
cantly decreased the number of sweat glands (P < 0.001) in 
the menopausal rats after 6 weeks of treatment.
In the plantar sweat glands of the young rats, the secre-
tory portions lay in clusters among the fat cells of the 
hypodermis. Irregular connective tissue of the dermis 
and numerous blood vessels were in the vicinity of the 
secretory portions (Fig.  8a). In the plantar sweat glands 
of the menopausal rats in the control group, the number 
of secretory cells had increased (Fig. 8b). Both the num-
ber of secretory cells and the number of vacuoles in the 
cells were significantly lower in the plantar sweat glands 
of the menopausal rats after treatment with all dosages of 
MEXD and Huangqijing (Fig. 8c–f).
Discussion
In this study, the anti-menopausal sweating effects of 
MEXD were evaluated using a 12–14-month-old aged 
menopausal SD rat model with both irregular estrous 
cycles and lowered serum E2 levels. All animal models 
have some limitations, and in this case, the age and physi-
ology of the rats cannot completely mimic human female 
menopause. The duration of the estrous cycle in SD rats 
is 3–4 days [27], and the lifespan of the rats is only 2.5–
3.5 years [28], while the human menstrual cycle occurs at 
approximately monthly intervals. During menopause, the 
ovarian function declines, but the ovaries still synthesize 
some steroid hormones such as androstenedione, tes-
tosterone, and E2 [29]. Thus, the use of ovariectomized 
female SD rats as an animal model of menopause cannot 
mimic the physiological states of menopause and ovarian 
aging in humans. A previous study demonstrated that SD 
rats have a fertility duration of 3–9  months, indicating 
that rats aged 12 months and older would correspond to 
the perimenopause phase in humans [28]. Our unpub-
lished data showed that 12-month-old SD rats under-
going natural aging demonstrated markedly reduced 
circulating E2 levels compared with 3-month-old rats, 
indicating that these rats may mimic the human female 
entering the menopause transition phase. Therefore, our 
animal model employing 12–14-month-old female SD 
Fig. 7 Antiperspirant effect of MEXD on rats foot pads (n = 10, mean ± standard deviation) one-way ANOVA followed by multiple. *P < 0.05, 
**P ≤ 0.01 and ***P < 0.001 compared with control. Week 3 young rats vs. control: P = 0.0012, MEXD (11 g/kg) vs. control: P = 0.0026, Huangqijing vs. 
control: P = 0.0032. Week 6 young rats vs. control: P < 0.0001, MEXD (5.5 g/kg) vs. control: P = 0.0005, MEXD (11 g/kg) vs. control: P < 0.0001, MEXD 
(5.5 g/kg) vs. control: P = 0.0034
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rats undergoing natural aging is reasonable. In this study, 
the estrous phase was determined by vaginal smears, and 
rats with irregular estrous cycles were regarded as meno-
pausal rats.
To exclude variations in bioactivity caused by incon-
sistency of herbal extract preparations, HPLC was 
used to evaluate the quality consistency of the MEXD 
extract prior to the animal experiments. Nine stand-
ard compounds, namely berberine, ferulic acid, icariin, 
jatrorrhizine, palmatine, schizandrol A, schizandrol B, 
schizandrin A, and schizandrin B, were selected as mark-
ers for evaluating the quality of MEXD (Fig. 1).
Five of these standard chemicals (jatorrhizine, berber-
ine, palmatine, ferulic acid, and icariin) are well-known 
compounds in EXD according to the Pharmacopoeia of 
the People’s Republic of China [30] and our previous pub-
lication [11]. All of these chemicals possess antioxidant 
activities. Moreover, three of them (ferulic acid, icariin, 
and berberine) exhibit estrogenic activity. Therefore, 
these constituents used for quality control are impor-
tant for the biological activity of the extract. Meanwhile, 
the markers for S. chinensis were not only the major 
components, but also possessed related pharmaceutical 
activities [31], including estrogenic and antioxidant activ-
ities. Besides, polysaccharides, free amino acids, lignans 
including schizandrol A, schizandrol B, schizandrin A, 
and schizandrin B were the major components in S. chin-
ensis, and have been commonly used for quality control 
Fig. 8 Secretory portions of rat plantar sweat glands in foot pads (indicated by solid black arrows). a Young rats; b control; c–e MEXD (5.5, 11 and 
22 g/kg) treated menopausal rats; f Huangqijing (5 mL/kg) treated menopausal rats. (H&E stain × 100)
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of S. chinensis [32–34]. Based on modern pharmaco-
logical studies, schizandrol A and schizandrin B possess 
antioxidant properties [35]. Schisantherin A manifests 
estrogenic effects [36]. The interassay RSD values were 
less than 5% for all nine standard compounds, indicat-
ing good quality of the MEXD extract and consistency 
between different batches of the MEXD extract (Table 1).
Aging is associated with higher levels of oxidative bio-
molecules reacting with free radicals [36–38]. Meno-
pause or ovariectomy (estrogen deficiency) can induce 
hot flashes and oxidative stress [38]. In addition, reac-
tive oxygen species attack the heme group of aromatase 
to inhibit E2 biosynthesis [39]. Previous studies demon-
strated that pulsatile release of FSH and LH is related to 
the mechanism underlying the initiation of hot flashes 
[40, 41]. Commonly, HRT effectively decreases oxida-
tive stress and relieves hot flashes [42], indicating that 
estrogen deficiency may increase oxidative stress and 
hot flashes physiologically. Besides, other studies indi-
cated that increased oxidative stress and MDA levels and 
decreased antioxidant enzyme SOD levels accompany 
hot flashes in menopausal women, and these symptoms 
were reversed after receiving HRT or undertaking yoga 
exercise [43–45]. The increased production of oxygen 
free radicals concomitant with aging accelerates the 
depletion of SOD and hinders SOD synthesis, leading 
to decreased SOD activity. In this study, the serum SOD 
activities of menopausal rats in the control group were 
significantly lower compared with those in the young rats 
(Fig. 2). The increased MDA contents indicated that lipid 
peroxidation became more active in menopausal rats, 
and the antioxidant abilities were declining. Our results 
revealed that MEXD at the dose of 11  g/kg effectively 
reduced serum MDA levels and promoted SOD activities 
(Figs. 2, 3). These findings demonstrate that MEXD treat-
ment can improve the antioxidant ability in aged female 
rats and potentially slow down the aging process.
The antioxidant activity of MEXD indicates its role in 
preventing reproductive aging. Along with reproductive 
aging, the activities of antioxidant enzymes and steroi-
dogenic enzymes including aromatase become lower, 
suggesting the association between an age-related envi-
ronment predominated by free radicals and a decrease 
in estrogen production through the effect on aromatase 
(Cyp19) activity in the human ovary [5]. It is known that 
E2 synthesis is mainly mediated by aromatase in ovarian 
granulosa cells [46]. Our previous publication [11] dem-
onstrated that one of the possible mechanisms underly-
ing the EXD-mediated relief of menopausal syndrome 
involves increases in endocrine function and serum E2 
levels through activation of ovarian aromatase. Moreover, 
recent findings suggest that the depletion of estrogen in 
the postmenopausal period can cause oxidative stress in 
addition to the known symptoms [47], given that E2 itself 
possesses antioxidative properties. Oxidative stress stim-
ulates hydroperoxide-dependent hydroxylation of E2 to 
catecholestrogen metabolites, which in turn can undergo 
reactive oxygen species-producing redox cycling, thus 
setting up a self-generating toxic cascade offsetting the 
antioxidant effects generated by the parent E2 [48]. In 
this study, treatment of menopausal female rats with 
MEXD promoted the serum activities of the antioxidative 
enzyme SOD (Fig. 2), thus possibly preventing the dam-
aging effect of free radicals on the aging ovaries.
Apart from the oxidative stress theory of reproduc-
tive aging, it is known that as the number of immature 
follicles declines with age, the negative feedback con-
trol of E2 on FSH secretion is relaxed, and therefore the 
basal circulating level of FSH increases. FSH orches-
trates the termination of folliculogenesis in ovaries, 
and high levels of FSH promote inappropriate matura-
tion of the granulosa cells of the residual prenatal folli-
cles. This asynchronous maturation of the germinal and 
somatic components results in follicular atresia, leading 
to a decrease in E2 production [49]. Among the MEXD-
treated groups, MEXD at the dosage of 11 g/kg restored 
the serum E2 levels (Fig. 4) and significantly reversed the 
increased FSH (Fig.  5) and LH (Fig.  6) levels compared 
with the control group. These results demonstrated that 
MEXD can improve the estrogen-deficient state in aged 
female rats and prevent reproductive aging. Moreover, 
the weights of the ovaries and uteri as well as their organ 
indices did not change after MEXD treatment, indicating 
that MEXD does not exert any observable adverse effects 
on the rat ovaries and uteri.
The regulatory effects of MEXD on menopausal hor-
mone profiles provide insights into interventions for 
vasomotor symptoms during menopause. According to 
the Dynamic Hypothesis, the most widely-accepted cur-
rent theory [4, 50], hot flashes and sweating result from 
the dynamic reduction or sudden deprivation of sex hor-
mones rather than their absolute plasma concentrations. 
Application of MEXD may reverse the estrogen decline 
during menopause, and thus prevent hot flashes and 
sweating. To elucidate the effects of MEXD on menopau-
sal sweating, Huangqijing oral liquor, an oral preparation 
composed of Radix Astragali extract, with the functions 
of replenishing Qi, nourishing blood, and reinforcing 
vital Qi to stop sweating according to Traditional Chi-
nese Medicine theory [51], was selected as the positive 
control. Our results revealed that sweating in the soles of 
menopausal rats in the control group increased signifi-
cantly, while MEXD at the dosage of 11 g/kg significantly 
reduced such sweating after both 3–6 weeks of treatment 
(Fig. 7). The results of the histological study also demon-
strated an increase in the number of sweat glands in the 
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soles of the menopausal rats (Fig.  8b). On the contrary, 
the MEXD-treated groups at all dosages (5.5, 11 and 
22 g/kg) exhibited conspicuous decreases in the number 
of secretory cells (Fig. 8c–e). Therefore, the potential effi-
cacy of MEXD against menopausal perspiration involves 
increases in endocrine function and serum E2 levels 
through the antioxidant activity pathways.
In Chinese medicine, through insufficiency of yin, 
yang cannot be preserved and the asthenia yang cannot 
guard yin, and thus yin is excreted in the form of sweat. 
Therefore, clinically, for restoring the kidney yin and 
yang, clinicians usually add S. chinensis. In Chinese med-
icine, the flavor of S. chinensis is sour, which can restrain 
body essence and nourish yin. A. sinensis together with S. 
chinensis can restore both liver blood and kidney essence, 
which is in accord with the theory of Chinese medicine 
that the liver and kidney share the same source. Taken 
together, the whole formula can nourish kidney yin by 
warming the kidney yang, and nourish yin to preserve 
asthenia yang, and when yin and yang reach a balance, 
menopausal sweating will cease. Chinese medicine 
mentions that Tian gui may refer to steroid hormones, 
including E2, which play a vital role in the reproductive 
system and the process of female menopause. In Chinese 
medicine, kidney-nourishing herb medicines can restore 
Tian gui, which mimics HRT in supplementing E2. This 
study also indicated that MEXD was able to promote E2 
biosynthesis (Fig. 4). Oral HRT was reported to be highly 
effective in alleviating hot flushes and night sweats [52]. 
The results of the present study using a menopausal rat 
model not only provide evidence to support the tradi-
tional Chinese medicine theory, but also shed new light 
on the effects of drugs in alleviating menopausal sweat-
ing and menopausal vasomotor symptoms. Interestingly, 
our study showed that the pharmacological activities 
of a Chinese medicine formula are different from those 
a pure chemical drug, as they did not show a dose-
dependent response. This finding also indicates that 
the complexity of Chinese medicines may be attributed 
to the interactions among multiple compounds within 
herbal medicines, and that their interactions in the body 
should be mediated in the manner of a network of inter-
molecular interactions. Further studies should investi-
gate the unique pharmacological activities of this herbal 
formula.
In essence, sweating falls within the scope of automatic 
temperature regulation. Previous studies suggested that 
hot flashes, consisting of sweating and peripheral vasodi-
lation, are triggered by small elevations in the core body 
temperature (CBT) acting within a reduced thermoneu-
tral zone in symptomatic postmenopausal women [53]. 
The narrowing of the zone may be caused by elevated cen-
tral noradrenergic activation and is probably precipitated 
by changes in estrogen [54]. Estrogen withdrawal 
increases the sensitivity of thermoregulatory neural path-
ways and modifies the activation of heat loss mechanisms. 
It was also reported that postmenopausal women with 
symptomatic hot flashes have a significantly lower rectal 
temperature for the sweating threshold, and their sweat-
ing rate is elevated, compared with their premenopausal 
counterparts [53]. In other words, sweating or hot flashes 
can reflect thermoregulatory dysfunction in menopau-
sal females. If the effects of MEXD can be identified by 
dynamic CBT monitoring, we speculate that the allevia-
tion of menopausal sweating by MEXD may be induced 
by restoration of the narrowed thermoneutral zone. Fur-
ther studies on the mechanism through which MEXD 
ameliorates menopausal perspiration are in progress.
Conclusion
Modified Erxian decoction significantly inhibited sweat 
excretion, regulated sex hormones, and exhibited anti-
oxidative effects in menopausal model rats.
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